Is PEG-MGF approved or legal?

PEG-MGF is not approved as a drug in any jurisdiction. It is prohibited in competitive sport by WADA since 2005 under the category of growth factors affecting muscle protein synthesis and regenerative capacity. It is sold for research use only. Black-market preparations have been confirmed by mass spectrometry to sometimes contain structural analogues distinct from the described peptide.

How is PEG-MGF different from IGF-1 or IGF-1 LR3?

MGF (mechano growth factor) is a splice variant of IGF-1 that produces a structurally distinct C-terminal Eb/Ec peptide. Unlike IGF-1, the E-domain peptide activates ERK without Akt, signals potentially through IGF-1R-independent pathways, and specifically activates muscle satellite cells and exerts anti-apoptotic cardiac effects through mitochondrial stabilisation. PEGylation extends its half-life from minutes to approximately 24–72 hours. IGF-1 LR3, by contrast, is a modified IGF-1 agonist acting through classical IGF-1R signaling.

What is PEG-MGF's half-life?

Native synthetic MGF E-domain peptide has an estimated half-life of minutes in systemic circulation. PEGylation extends this to approximately 24–72 hours based on polymer delivery system data; the precise pharmacokinetics of subcutaneous PEG-MGF in any species have not been formally published in peer-reviewed literature. No human pharmacokinetic data exist.

Does PEG-MGF build muscle?

In rodent and cell-based models, MGF E-domain peptide activates muscle satellite cells via IGF-1R-independent ERK signaling, and animal data show muscle hypertrophy-relevant effects. However, no human clinical trial has evaluated PEG-MGF for muscle mass or any other outcome. Community use is based entirely on mechanistic extrapolation and anecdote. Human benefit has not been demonstrated.

Human safety data are absent. Theoretical concerns include tumour promotion (IGF-1Ec is overexpressed in colorectal and prostate cancers, and its E-peptide stimulates cancer cell proliferation via IGF-1R-independent pathways), cardiac remodelling effects with chronic use, PEG polymer accumulation, and uncharacterised product quality in unregulated preparations. It is not recommended for human use.

Is there a difference between PEG-MGF and native MGF?

Yes. Native MGF is expressed endogenously at sites of mechanical stress, acting as a local (autocrine/paracrine) signal with very short half-life. Synthetic PEG-MGF is the same or similar E-domain peptide with PEG chains attached to extend systemic half-life. An important caveat: it is uncertain whether the 24-amino acid synthetic E-domain peptide accurately mirrors what is produced endogenously, as no such fragment has been isolated from living tissue.

Hormonal

PEG-MGF

Also known as: PEGylated Mechano Growth Factor, PEGylated IGF-1Ec, PEG-IGF-1Ec, Polyethylene Glycol-Mechano Growth Factor

A PEGylated synthetic form of mechano growth factor (the IGF-1Ec splice variant), studied preclinically for muscle satellite cell activation, cardioprotection, and...

Last updated July 11, 2026

Buy PEG-MGF

Overview

PEG-MGF is the polyethylene glycol (PEG)-conjugated form of Mechano Growth Factor (MGF), itself the IGF-1Ec splice variant of insulin-like growth factor 1 (IGF-1). MGF is produced in skeletal muscle, cardiac tissue, and other tissues in response to mechanical stretch and injury; it was first characterised by Geoffrey Goldspink's group in 1999 as the splice variant containing a 52 base-pair insert in exon 5 that causes a reading-frame shift, producing a distinct C-terminal Eb/Ec peptide structurally unrelated to any other IGF-1 isoform. Native endogenous MGF has very short local half-life, functioning as an autocrine/paracrine signal at sites of mechanical stress. PEGylation — attachment of polyethylene glycol chains — is a well-established pharmaceutical strategy to extend peptide half-life; applied to the 24-amino acid synthetic MGF E-domain peptide, it converts the molecule from one with minutes of systemic availability to a form with an estimated half-life of approximately 24–72 hours following subcutaneous injection, substantially increasing systemic exposure. All published research on MGF and PEG-MGF is preclinical: rodent and in vitro models demonstrating muscle satellite cell activation, cardiac protection after myocardial infarction, ALS motor neuron rescue, and age-related neurogenesis promotion. No human clinical trial has been published evaluating PEG-MGF for any indication. PEG-MGF is prohibited in competitive sport by WADA (banned since 2005 under growth factors affecting muscle regeneration). Illicit synthetic preparations have been confirmed in black-market products by mass spectrometry. All human use occurs without regulatory oversight. This is a research compound only.

How it works

MGF's 24-amino acid C-terminal E-domain peptide (Eb/Ec peptide) acts through mechanisms distinct from canonical IGF-1 receptor (IGF-1R) signalling. Published preclinical data indicate: 1. Satellite cell activation: MGF E-domain stimulates ERK phosphorylation independently of IGF-1R (without activating Akt), and acts at a molecular level that may include intracrine/nuclear signalling. It activates muscle satellite (stem) cells and maintains them in a proliferative, non-differentiated state — actions temporally distinct from those of IGF-1Ea, which drives later differentiation and protein synthesis. 2. Anti-apoptotic / cardioprotective: E-domain peptide blocks the intrinsic apoptotic pathway in cardiac cells by preventing mitochondrial membrane potential collapse and suppressing caspase-3 activation — a mechanism distinct from the PI3K/Akt survival pathway activated by classical IGF-1. 3. Temporal sequence in tissue repair: MGF expression peaks within 1 day of muscle injury (preceding satellite cell marker M-cadherin by 4–5 days), initiating satellite cell recruitment; IGF-1Ea expression rises later and sustains the differentiation/repair phase. PEGylation extends systemic exposure of the E-domain beyond the endogenous paracrine context. These mechanisms are established in cell culture and rodent models. The degree to which exogenously administered PEG-MGF replicates endogenous MGF biology in humans is unknown; a critical caveat is that no stable 24-amino acid peptide matching the synthetic E-domain has been isolated from living tissue, and it remains unclear whether endogenous proteolytic processing generates this exact fragment in vivo.

Researched effects

Preclinical Activates muscle satellite (stem) cells to proliferate after mechanical injury, via IGF-1R-independent ERK signaling
Preclinical Reduces cardiac cell apoptosis and preserves contractile function in rodent myocardial infarction models
Preclinical Rescues motor neurons and improves hindlimb muscle strength in ALS (SOD1 G93A) mouse models
Preclinical Promotes neurogenesis (dentate gyrus and subventricular zone proliferation) in aging mice
Preclinical Reduces pathological cardiac hypertrophy and prevents embryonic gene re-expression post-MI in rodents
Anecdotal Accelerates muscle recovery and increases lean mass gains
Anecdotal Acts synergistically with IGF-1 LR3 in promoting muscle hypertrophy

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established or approved clinical dosing in humans. No human clinical trial of MGF or PEG-MGF has been published for any indication. Human pharmacokinetics, minimum effective dose, maximum tolerated dose, and safety profile are not characterised in peer-reviewed literature. There is no regulatory reference dose.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice or instruction. Community protocols (bodybuilding forums and research peptide communities) most commonly describe intramuscular or subcutaneous injections of 200–400 mcg, one to two times per week. Rationale offered anecdotally is the extended PEGylated half-life permitting less frequent dosing compared to native MGF. Some community protocols combine PEG-MGF with IGF-1 LR3, theorising additive satellite cell and IGF-1R-mediated effects. No human safety or efficacy data support any of these protocols.

Half-life: Native synthetic MGF E-domain peptide has very short systemic half-life (estimated minutes in circulation, consistent with its autocrine/paracrine physiological role). PEGylation dramatically extends this; polymeric PEG delivery systems and PEGylated peptide conjugates in the literature demonstrate release and peptide stability of approximately 24–72 hours, which is the figure typically cited for PEG-MGF. Precise pharmacokinetics of commercially available PEG-MGF (subcutaneous injection in humans) have not been formally characterised in any published human or animal pharmacokinetic study.
Routes: subcutaneous, intramuscular

Safety & side effects

Long-term human safety data are completely absent; no clinical trial has been conducted. Theoretical safety concerns include: Oncology risk: IGF-1Ec (MGF) is overexpressed in colorectal cancer and prostate cancer tissue relative to normal tissue, and the synthetic E-domain peptide stimulates prostate cancer cell proliferation through an IGF-1R-independent mechanism. This suggests exogenous PEG-MGF could promote tumour growth through pathways not blocked by IGF-1R inhibitors. Cardiac hypertrophy: While preclinical data show cardioprotection in acute MI models, chronic sustained IGF-1 axis activation is associated with pathological cardiac hypertrophy; long-term PEG-MGF effects on cardiac remodelling in healthy hearts are unstudied. PEG polymer concerns: High-molecular-weight PEG conjugates can accumulate in certain tissues with chronic use; PEG-related immune responses (anti-PEG antibodies) have been documented with other PEGylated biologics. Product quality: Black-market and research-grade PEG-MGF has been found by mass spectrometry to contain structural analogues (C-terminal amidated forms) not matching the endogenous peptide sequence, introducing additional pharmacological and safety uncertainty. PEG-MGF is prohibited in competitive sport by WADA (banned since 2005 under growth factors affecting muscle protein synthesis, vascularisation, regenerative capacity, or fibre type switching). It is not an approved drug in any jurisdiction. This information is for research reference only.

Research summary

The preclinical evidence base for MGF and PEG-MGF is scientifically coherent and covers multiple tissue types: skeletal muscle satellite cell biology (McKoy et al., J Physiol 1999; Hill et al., J Anat 2003), cardiac protection (Mavrommatis et al., Mol Cell Biochem 2013; Pena et al., Biomaterials 2015), neurological rescue in ALS (Riddoch-Contreras et al., Exp Neurol 2009), and neurogenesis in aging (Tang et al., Mol Brain 2017). The mechanistic picture is interesting and partially differentiated from classical IGF-1 biology: E-domain peptide activates ERK without Akt (unlike IGF-1), may signal intracellularly, maintains satellite cells in proliferation without premature differentiation, and exerts anti-apoptotic cardiac effects through mitochondrial membrane stabilisation rather than PI3K/Akt. These distinctions make MGF genuinely novel rather than simply redundant with IGF-1. However, several critical questions limit confidence even in the preclinical picture: (1) whether an endogenous 24-amino acid E-domain peptide is actually produced by proteolytic processing in vivo remains uncertain — no such fragment has been isolated from living tissue; (2) the pharmacokinetics of subcutaneously injected PEG-MGF in any species are not published in peer-reviewed literature; (3) cancer overexpression data (IGF-1Ec in colorectal and prostate tumours) introduces a meaningful preclinical safety signal. The human evidence gap is total. No published RCT, observational study, or even formal pharmacokinetic study in humans exists. Community use is based entirely on mechanistic extrapolation and anecdote. PEG-MGF should be classified as a promising but entirely unproven research compound with uncharacterised human safety and no validated therapeutic application.

FAQ

Is PEG-MGF approved or legal?: PEG-MGF is not approved as a drug in any jurisdiction. It is prohibited in competitive sport by WADA since 2005 under the category of growth factors affecting muscle protein synthesis and regenerative capacity. It is sold for research use only. Black-market preparations have been confirmed by mass spectrometry to sometimes contain structural analogues distinct from the described peptide.
How is PEG-MGF different from IGF-1 or IGF-1 LR3?: MGF (mechano growth factor) is a splice variant of IGF-1 that produces a structurally distinct C-terminal Eb/Ec peptide. Unlike IGF-1, the E-domain peptide activates ERK without Akt, signals potentially through IGF-1R-independent pathways, and specifically activates muscle satellite cells and exerts anti-apoptotic cardiac effects through mitochondrial stabilisation. PEGylation extends its half-life from minutes to approximately 24–72 hours. IGF-1 LR3, by contrast, is a modified IGF-1 agonist acting through classical IGF-1R signaling.
What is PEG-MGF's half-life?: Native synthetic MGF E-domain peptide has an estimated half-life of minutes in systemic circulation. PEGylation extends this to approximately 24–72 hours based on polymer delivery system data; the precise pharmacokinetics of subcutaneous PEG-MGF in any species have not been formally published in peer-reviewed literature. No human pharmacokinetic data exist.
Does PEG-MGF build muscle?: In rodent and cell-based models, MGF E-domain peptide activates muscle satellite cells via IGF-1R-independent ERK signaling, and animal data show muscle hypertrophy-relevant effects. However, no human clinical trial has evaluated PEG-MGF for muscle mass or any other outcome. Community use is based entirely on mechanistic extrapolation and anecdote. Human benefit has not been demonstrated.
Is PEG-MGF safe?: Human safety data are absent. Theoretical concerns include tumour promotion (IGF-1Ec is overexpressed in colorectal and prostate cancers, and its E-peptide stimulates cancer cell proliferation via IGF-1R-independent pathways), cardiac remodelling effects with chronic use, PEG polymer accumulation, and uncharacterised product quality in unregulated preparations. It is not recommended for human use.
Is there a difference between PEG-MGF and native MGF?: Yes. Native MGF is expressed endogenously at sites of mechanical stress, acting as a local (autocrine/paracrine) signal with very short half-life. Synthetic PEG-MGF is the same or similar E-domain peptide with PEG chains attached to extend systemic half-life. An important caveat: it is uncertain whether the 24-amino acid synthetic E-domain peptide accurately mirrors what is produced endogenously, as no such fragment has been isolated from living tissue.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.